C. Adenis

发表

Patients' characteristics and rate of Internet use to obtain cancer information.

Valérie Bonadona, Dominique Stoppa-Lyonnet, D. Stoppa-Lyonnet, 2006, Journal of public health.

Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing

M. Bihoreau, N. Servant, D. Stoppa-Lyonnet, 2018, International journal of cancer.

Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

W. Chung, J. Benítez, R. Eeles, 2020, Breast Cancer Research.

Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families

K. Dahan, D. Stoppa-Lyonnet, B. Gilbert-Dussardier, 2017, Carcinogenesis.

Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development.

J. Peyrat, E. Leblanc, F. Narducci, 2011, Gynecologic oncology.

A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers

F. Révillion, Chloé-Agathe Azencott, N. Sevenet, 2020, BMC Medical Research Methodology.

Prostate cancer related haemophagocytic syndrome: Successful treatment with chemotherapy

N. Penel, A. Adenis, A. Caty, 2012, Acta oncologica.

Germline BRCA1 mutations in patients from 84 families with breast and/or ovarian cancers in northern France

L. Hornez, J. Bonneterre, J. Peyrat, 1997, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Nonrandom 4p13 rearrangements of the RhoH/TTF gene, encoding a GTP-binding protein, in non-Hodgkin's lymphoma and multiple myeloma

C. Preudhomme, P. Fenaux, F. Bauters, 2000, Oncogene.

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

R. Eeles, J. Hopper, D. Easton, 2021, American journal of obstetrics and gynecology.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

GENESIS: a French national resource to study the missing heritability of breast cancer

D. Stoppa-Lyonnet, O. Sinilnikova, S. Mazoyer, 2016, BMC Cancer.

Evaluation and use of the white blood cell differential provided by the Coulter STKS in a children's hospital.

J. Goudemand, B. Carnaille, C. Adenis, 2008, Clinical and laboratory haematology.

No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study

F. Couch, I. Ellis, T. Rebbeck, 2009, Breast Cancer Research and Treatment.

Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing.

D. Stoppa-Lyonnet, A. Chompret, J. Fricker, 2006, European journal of cancer.

Comparison of the Screening Practices of Unaffected Noncarriers under 40 and between 40 and 49 in BRCA1/2 Families

J. Peyrat, I. Milhabet, V. Christophe, 2013, Journal of Genetic Counseling.

[Information spreading about hereditary carriage of a BRCA1/2 mutation and ovarian cancer and rate of consultation of the concerned relatives].

T. Leroy, V. Christophe, P. Vennin, 2008, Bulletin du cancer.

Large-cell medulloblastoma with arrestin-like protein expression.

C. Maurage, F. Giangaspero, M. Ruchoux, 2003, Clinical Neuropathology.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Jane E. Carpenter, W. Chung, M. Beckmann, 2019, npj Breast Cancer.